Stress, the body's natural response to different types of challenges and daily problems, is an inherently harmless state ...

The gonadotropin hormone receptors, including the follicle-stimulating hormone receptor (FSHR) and the luteinizing hormone/choriogonadotropin receptor (LH/CGR), serve as integral mediators of ...

Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone that is ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

In a comprehensive review published in the October 2024 issue of Genomic Psychiatry, researchers have unveiled crucial insights into how two types of hormone receptors collaborate to maintain brain ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 6, 2026 (HealthDay News) — A drug that mimics the female hormone ...

ER+/PR+ breast cancer is a subtype of ER positive breast cancer where the tumor cells express both estrogen receptors (ER) and progesterone receptors (PR) on the surface. As the most common type of ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...